Department of General Surgery, Abdulkadir Yuksel State Hospital, Gaziantep, Turkey.
Department of Radiology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.
Am Surg. 2024 Feb;90(2):252-260. doi: 10.1177/00031348231199174. Epub 2023 Aug 30.
In this study, it was aimed to evaluate the characteristic features and survival of secretory carcinoma of the breast (SCB), which is one of the rare malignant tumors of the breast.
Data of patients with histopathological diagnosis of SCB between 2010 and 2019 were extracted from the SEER database. These patients were evaluated in terms of age, race, molecular subtype, grade, estrogen receptor (ER), progesterone receptor (PR), HER2 receptor, TNM stage, surgical status, chemotherapy and radiotherapy treatment. Overall survival (OS) and breast cancer-specific survival (BCSS) of the whole population and subgroups [in terms of surgery procedure (mastectomy/breast-conserving surgery), and hormone receptor status (positive/negative)] were analyzed.
70 patients were included in the study. The mean age was 57 years (range 2-82). 32.9% of the patients were diagnosed under the age of 50. 97.1% of the patients were female; 2.9% were male. The vast majority of patients were white race (81.4%). Although the rates of localization were higher in the upper outer quadrant (31.4%), centrally located tumors (18.5%) were also quite common. The most frequently detected molecular subtype was hormone positive/HER2 negative. All patients were non-metastatic, 81.4% of patients did not have lymph node metastases, and most of the patients were stage IA. Median follow-up was 37 months (range 0-118 months). Considering all patients, OS was 76.3%, 5-year OS was 91.8%, and BCSS was 88%, 5-year BCSS was 97.8%. There was no statistically significant difference in OS and BCSS according to subgroups ( > .01).
SCB, a rare histopathologic type, has high OS and BCSS rates.
本研究旨在评估乳腺分泌性癌（SCB）的特征和生存情况，SCB 是一种罕见的乳腺恶性肿瘤。
从 SEER 数据库中提取了 2010 年至 2019 年间组织病理学诊断为 SCB 的患者数据。这些患者根据年龄、种族、分子亚型、分级、雌激素受体（ER）、孕激素受体（PR）、HER2 受体、TNM 分期、手术情况、化疗和放疗进行评估。分析了全人群和亚组（手术方式[乳房切除术/保乳手术]和激素受体状态[阳性/阴性]）的总生存（OS）和乳腺癌特异性生存（BCSS）。
本研究共纳入 70 例患者。平均年龄为 57 岁（范围 2-82 岁）。32.9%的患者年龄在 50 岁以下。97.1%的患者为女性；2.9%为男性。绝大多数患者为白种人（81.4%）。虽然肿瘤位于外上象限的比例较高（31.4%），但位于中央的肿瘤（18.5%）也很常见。最常见的分子亚型是激素阳性/HER2 阴性。所有患者均为非转移性，81.4%的患者无淋巴结转移，且大多数患者为 IA 期。中位随访时间为 37 个月（范围 0-118 个月）。考虑到所有患者，OS 为 76.3%，5 年 OS 为 91.8%，BCSS 为 88%，5 年 BCSS 为 97.8%。亚组间 OS 和 BCSS 无统计学差异（>0.01）。
SCB 是一种罕见的组织病理学类型，具有较高的 OS 和 BCSS 率。
